Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
fluoroquinolone |
| gptkbp:approvalYear |
1999
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J01MA14
|
| gptkbp:brand |
gptkb:Vigamox
gptkb:Moxiflo gptkb:Avelox |
| gptkbp:CASNumber |
gptkb:151096-09-2
|
| gptkbp:chemicalFormula |
gptkb:C21H24FN3O4
|
| gptkbp:contraindication |
children
pregnancy hypersensitivity to quinolones |
| gptkbp:discoveredBy |
gptkb:Bayer_AG
|
| gptkbp:eliminationHalfLife |
12 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
moxifloxacin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous ophthalmic |
| gptkbp:sideEffect |
nausea
diarrhea headache QT prolongation |
| gptkbp:usedFor |
skin infections
bacterial infections respiratory tract infections intra-abdominal infections |
| gptkbp:bfsParent |
gptkb:Fluoroquinolones
gptkb:Avelox |
| gptkbp:bfsLayer |
5
|